Literature DB >> 20222159

Steatosis as a co-factor in chronic liver diseases.

Marcello Persico1, Achille Iolascon.   

Abstract

The finding of lipid accumulation in the liver, so-called hepatic steatosis or non-alcoholic fatty liver disease, is a common condition frequently found in healthy subjects. Its prevalence, in fact, has been estimated by magnetic resonance studies to be about 35% in the general population and 75% in obese persons. Nevertheless, its presence generates liver damage only in a small percentage of subjects not affected by other liver diseases. It should be defined as a "co-factor" capable of affecting severity and progression, and also therapeutic perspectives, of liver diseases to which it is associated. Herein we will evaluate the impact of hepatic steatosis and obesity on the most common liver diseases: chronic viral hepatitis C and B, and alcoholic liver disease.

Entities:  

Mesh:

Year:  2010        PMID: 20222159      PMCID: PMC2839168          DOI: 10.3748/wjg.v16.i10.1171

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  57 in total

Review 1.  The spectrum of liver disease in the general population: lesson from the Dionysos study.

Authors:  S Bellentani; C Tiribelli
Journal:  J Hepatol       Date:  2001-10       Impact factor: 25.083

Review 2.  Interaction of non-alcoholic fatty liver disease with other liver diseases.

Authors:  Andrew D Clouston; Elizabeth E Powell
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-10       Impact factor: 3.043

3.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

4.  Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.

Authors:  J Crespo; A Cayón; P Fernández-Gil; M Hernández-Guerra; M Mayorga; A Domínguez-Díez; J C Fernández-Escalante; F Pons-Romero
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

5.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.

Authors:  L E Adinolfi; M Gambardella; A Andreana; M F Tripodi ; R Utili; G Ruggiero
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Risk factors of fibrosis in alcohol-induced liver disease.

Authors:  Bruno Raynard; Axel Balian; David Fallik; Frédérique Capron; Pierre Bedossa; Jean-Claude Chaput; Sylvie Naveau
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

7.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

Authors:  I J Hickman; A D Clouston; G A Macdonald; D M Purdie; J B Prins; S Ash; J R Jonsson; E E Powell
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

8.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

Authors:  Satheesh Nair; Andrew Mason; James Eason; George Loss; Robert P Perrillo
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

9.  Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.

Authors:  Marcello Persico; Mario Masarone; Vincenzo La Mura; Eliana Persico; Francesco Moschella; Monica Svelto; Savino Bruno; Roberto Torella
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

10.  Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.

Authors:  Alexander Monto; Judy Alonzo; Jessica J Watson; Carl Grunfeld; Teresa L Wright
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  16 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

Review 3.  Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.

Authors:  Ludovico Abenavoli; Mario Masarone; Valentina Peta; Natasa Milic; Nazarii Kobyliak; Samir Rouabhia; Marcello Persico
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 4.  The weight of obesity on the human immune response to vaccination.

Authors:  Scott D Painter; Inna G Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2015-07-08       Impact factor: 3.641

Review 5.  Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease.

Authors:  Bratati Kahali; Brian Halligan; Elizabeth K Speliotes
Journal:  Semin Liver Dis       Date:  2015-12-16       Impact factor: 6.115

6.  Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis.

Authors:  Rui-dan Zheng; Cheng-run Xu; Li Jiang; Ai-xia Dou; Kun Zhou; Lun-gen Lu
Journal:  Int J Med Sci       Date:  2010-08-11       Impact factor: 3.738

7.  Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome.

Authors:  Nishika Sahini; Saravanakumar Selvaraj; Jürgen Borlak
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

8.  Predictors of Diarrhea after Hepatectomy and Its Impact on Gastrointestinal Quality of Life in Living Donors.

Authors:  Szu-Han Wang; Ying-Zi Ming; Ping-Yi Lin; Jiun-Yi Wang; Hui-Chuan Lin; Chia-En Hsieh; Ya-Lan Hsu; Yao-Li Chen
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease.

Authors:  Li-Yao Zhu; Yu-Gang Wang; Li-Qing Wei; Jian Zhou; Wei-Jie Dai; Xiao-Yu Zhang
Journal:  Drug Des Devel Ther       Date:  2016-08-30       Impact factor: 4.162

Review 10.  ROS homeostasis, a key determinant in liver ischemic-preconditioning.

Authors:  Ignacio Prieto; María Monsalve
Journal:  Redox Biol       Date:  2017-05-04       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.